Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOMENTUM: Phase 2 DNTH103 in adults with multifocal motor neuropathy
NL-OMON59763Phase 2Active, not recruiting
- Sponsor
- Dianthus Therapeutics
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of claseprubart in multifocal motor neuropathy (MMN) (3 arms), sponsored by Dianthus Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events and serious adverse events. Started Jul 2025; status: active, not recruiting.
02
Drugs
claseprubart
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on NL-OMON59763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59763.